MaxCyte Latest News

From advances in cell therapy to changes at MaxCyte®, the past few months have been busy. Through it all, we remain committed to helping you solve the toughest cell engineering challenges with our proven ExPERT™ platform and trusted support. This issue of MaxCyte Minutes Newsletter has a lot in store! Let’s dive in. Read more. . . .

TG Therapeutics to use MaxCyte’s Flow Electroporation^® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases

This strategic acquisition strengthens MaxCyte’s ability to serve ex vivo and in vivo cell and gene therapy (CGT) developers with an innovative suite of tools and services spanning early R&D through clinical development and commercialization. By integrating SeQure Dx into MaxCyte, Maxcyte will expand its service offerings and leverage its commercial and field application scientist teams to work with developers earlier in their research processes. SeQure Dx is revenue generating and expected to be accretive to MaxCyte’s revenue growth.

In the last three months, new collaboration between the University of California San Diego Sanford Stem Cell Institute (SSCI) and MaxCyte, Webinar on Next-Generation genetic discovery systems in human immune cells, Scientific poster on High efficiency complex gene editing of hard-to-transfect primary cells using MaxCyte electroporation in combination with Synthego sgRNAs.

Jeremy Kolenbrander is Senior VP of Product Development and Engineering at MaxCyte, he was drawn to cell and gene therapy as it has the ability to make a huge difference in the lives of patients and their caregivers. He joined MaxCyte in early in 2024.

MaxCyte marks over a quarter-century remaining steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health.

New collaboration aims to improve patient outcomes and boost biopharma workforce development.

Cynthia Collins joins the board with extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years.

Ali Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the company’s market impact in cell and gene therapy.

In the last three months, Kamau Therapeutics became a strategic platform licensee partner, Porton Advance adopted the ExPERT GTx Flow Electroporation as part of their offerings, and ScaleReady and MaxCyte have collaborated on the G-Rex Grant Program to support cell and gene therapy advancements.